Invivogen
Menu

SARS-CoV-2 Nucleocapsid Proteins

Nucleocapsid-His Unit size Cat. code Docs Qty Price
SARS-CoV-2 Nucleocapsid-His fusion protein
50 µg
his-sars2-n
+-
$210.00
Nucleocapsid-Fc Unit size Cat. code Docs Qty Price
SARS-CoV-2 Nucleocapsid-Fc fusion protein
50 µg
fc-sars2-n
+-
$210.00

SARS-CoV-2 Nucleocapsid with C-term His- or Fc-tag

PROTEIN DESCRIPTION

Potential applications of soluble tagged Spike S1 proteins
Potential applications of soluble tagged Nucleocapsid proteins

The SARS-CoV-2 (2019-nCoV) Nucleocapsid (N) is a structural protein that plays important roles in the viral life cycle including replication, transcription, and genome packaging [1]. The SARS-CoV-2 N features two important NTD and CTD functional domains [1-6]. NTD interacts with both the RNA genome and Membrane/Matrix (M) proteins to form virion particles. The N protein interaction with the RNA forms the virus ribonucleoprotein core which is packed as a helical “beads-on-a-string” conformation. CTD allows RNA synthesis through binding of the replication-transcription complexes (RTCs), oligomerization of multiple N proteins through its dimerization domain, and genome incorporation into the new virion.
N is a major immunogen of SARS-CoV-2. Indeed, elevated Anti-SARS-CoV-2 N IgG and IgM antibody titers have been reported in COVID-19 patients’ sera [7-9]. These observations make SARS-CoV-2 N an attractive tool for early diagnosis [7-9], and treatment strategies [3].
 

Nucleocapsid-His and Nucleocapsid-Fc were generated by fusing the full-length SARS-CoV-2 N [M1-A419] to a C-terminal poly-histidine sequence and human IgG1 Fc region, respectively. Of note, the SARS-CoV-2 viral sequence used is from the Wuhan-Hu-1 (D614) isolate. 

Nucleocapsid-His and Nucleocapsid-Fc have been produced in CHO cells and HEK293 cells, respectively, and have been purified by affinity chromatography (See Specifications for more information).

 

APPLICATIONS

  • Vaccination studies: using combinations of Nucleocapsid protein antigens and adjuvants
  • Antibody screening:  finding anti-Nucleocapsid antibodies in COVID-19 patients' sera
  • Inhibitor screening: finding small molecules able to block the SARS-CoV-2 Nucleocapsid interaction with replication-transcription complexes (RTCs)

QUALITY CONTROL

  • Size and purity confirmed by SDS-PAGE
  • Protein validated by ELISA using a coated anti-SARS Nucleocapsid antibody

 

Learn more on SARS-CoV-2Learn more about SARS-CoV-2 infection cycle, immune responses, and potential therapeutics.

 

References

1. Mu, J. et al., 2020. SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells. Sci China Life Sci 63, 1-4.
2. Chang C. et al., 2006. Modular organization of SARS coronavirus nucleocapsid protein. J. Biom. Sci. 13:59-72.
3. Krokhin O. et al., 2003. Mass spectrometric characterization of proteins from the SARS virus. Mol. & Cell. Prot. 2:346-356.
4. Cubuk, J. et al., 2020. The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. bioRxiv. doi:10.1101/2020.06.17.158121.
5. Kang, S.et al., 2020. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B. doi:10.1016/j.apsb.2020.04.009.
6. Khan, M.T. et al., 2020. SARS-CoV-2 nucleocapsid and Nsp3 binding: an in silico study. Arch Microbiol. doi: 10.1007/s00203-020-01998-6.
7. Liu, W. et al., 2020. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. J Clin Microbiol 58.
8. Guo L. et al., 2020. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clinical Infectious Diseases. 71(15) :778-785.
9. To K. K-W. et al., 2020. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases. 20(5):565-574.

Figures

Nucleocaspid-His purity analysis by SDS-PAGE
Nucleocaspid-His purity analysis by SDS-PAGE

SDS-PAGE analysis of the SARS-CoV-2 Nucleocapsid-His protein.
2 μg of the fusion protein was loaded onto a 12% Mini-PROTEAN® TGX Stain-Free™ Precast Gel (Bio-Rad). Detection was performed as per manufacturer’s instructions.

Recognition of Nucleocapsid-His by anAnti-SARS-CoV-Nucleocaspid mouse IgG1
Recognition of Nucleocapsid-His by anAnti-SARS-CoV-Nucleocaspid mouse IgG1

ELISA detection of Nucleocapsid-His fusion protein with an Anti-SARS-CoV-Nucleocapsid mAb.
Anti-SARS-CoV-Nucleocapsid antibody (2 μg/ml) was coated onto ELISA plates overnight. Following this, a 2-fold serial dilution of Nucleocapsid-His (red curve) or control protein (Spike-RBD-His; grey curve) were added and incubated for 1 hour.  Binding was detected using a HRP-labelled  anti-His  antibody  (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine  dihydrochloride). Absorbance was read at 490 nm.

Nucleocaspid-Fc purity analysis by SDS-PAGE
Nucleocaspid-Fc purity analysis by SDS-PAGE

SDS-PAGE analysis of the SARS-CoV-2 Nucleocapsid-Fc protein.
2 μg of the fusion protein was loaded onto a 12% Mini-PROTEAN® TGX Stain-Free™ Precast Gel (Bio-Rad). Detection was performed as per manufacturer’s instructions.

Recognition of Nucleocapsid-Fc by anAnti-SARS-CoV-Nucleocaspid mouse IgG1
Recognition of Nucleocapsid-Fc by anAnti-SARS-CoV-Nucleocaspid mouse IgG1

ELISA detection of Nucleocapsid-Fc fusion protein with an Anti-SARS-CoV-Nucleocapsid mAb.
Anti-SARS-CoV-Nucleocapsid antibody (2 μg/ml) was coated onto ELISA plates overnight. Following this, a 3-fold serial dilution of Nucleocapsid-Fc (red curve) or control protein (Dectin-Fc;  grey  curve) were added and incubated for 1 hour. Binding was detected using a HRP-labelled  anti-His antibody (1/1000  dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride).Absorbance was read at 490 nm.

Back to the top

Specifications

Nucleocapsid-His

  • Protein construction: Full-length Nuceocapsid with a C-terminal poly-histidine tag 
  • Accession sequence: P0DTC9
  • Species: SARS-CoV-2 (2019-nCoV); Wuhan-Hu-1 (D614) isolate
  • Tag: C-terminal poly-histidine (6 x His)
  • Total protein size: 430 a.a. (secreted form)
  • Molecular weight: ~ 52 kDa (SDS PAGE gel)
  • Purification: Ni2+ affinity chromatography
  • Purity: >95% (SDS PAGE)
  • Quality control:
    - The protein has been validated by ELISA upon incubation with an Anti-SARS Nucleocapsid antibody.
    - The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cellular assays.

Nucleocapsid-Fc

  • Protein construction: Full-length Nuceocapsid with a C-terminal human IgG1 Fc tag 
  • Accession sequence: P0DTC9
  • Species: SARS-CoV-2 (2019-nCoV); Wuhan-Hu-1 (D614) isolate
  • Tag: C-terminal human IgG1 Fc
  • Total protein size: 669 a.a. (secreted form)
  • Molecular weight: ~ 79 kDa (SDS PAGE)
  • Purification: Protein G affinity chromatography
  • Purity: >95% (SDS PAGE)
  • Quality control:
    - The protein has been validated by ELISA upon incubation with an Anti-SARS Nucleocapsid antibody. 
    - The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cellular assays.
Back to the top

Contents

Nucleocapsid-His and Nucleocapsid-Fc contents:

  • 50 μg of lyophilized protein
  • 1.5 ml of endotoxin-free water

room temperature The product is shipped at room temperature.

store Lyophilized protein should be stored at -20 ̊C.

stability Resuspended protein is stable up to 1 month when stored at 4°C, and 1 year when stored at -20°C

Avoid repeated freeze-thaw cycles.

Back to the top

Details

Learn more about the SARS-CoV-2 Nucleocapsid protein here.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty